(Q34696315)

4 August 2017

1 reference

title

Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma (English)

1 reference

4 August 2017

1 reference

Thierry Alcindor

1

1 reference

4 August 2017

Thomas E Witzig

series ordinal

2

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Current Treatment Options in Oncology

4 August 2017

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

275-282

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-002-0027-y

4 August 2017

exact match

0 references

cites work

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1 reference

12 December 2020

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

1 reference

12 December 2020

Radiolabeled antibody therapy of B-cell lymphomas

1 reference

12 December 2020

Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

1 reference

12 December 2020

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma

1 reference

12 December 2020

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

1 reference

12 December 2020

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

12 December 2020

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

1 reference

12 December 2020

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Unexplained increases in cancer incidence in the United States from 1975 to 1994: possible sentinel health indicators?

1 reference

12 December 2020

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

12 December 2020

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

1 reference

12 December 2020

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

12 December 2020

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

1 reference

12 December 2020

Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

12 December 2020

10.1007/S11864-002-0027-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1007961881

0 references

1 reference